Prognostic significance of CT-determined sarcopenia in older patients with advanced squamous cell lung cancer treated with programmed death-1 inhibitors
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Sarcopenia has been associated with higher toxicity induced by anti-cancer treatments and shorter survival in patients with squamous cell lung carcinoma (SqCLC). Over the past few decades, immune checkpoint inhibitors (ICIs) significantly improves the prognosis. However, few clinical studies explored the effectiveness of immunotherapy in the elderly population. Here, we performed a retrospective analysis to determine the prognostic role of sarcopenia in older patients with SqCLC receiving ICIs. We retrospectively assessed SqCLC patients who were treated with PD-1 inhibitors and all patients were at least 70 years old. Pre-treatment sarcopenic status was determined by analyzing L3 skeletal muscle index (SMI) with chest CT. Progression-free survival (PFS), disease-specific survival (DSS) and overall survival (OS) were estimated using the Kaplan–Meier method, and the differences in survival were compared using the log-rank test. Among 130 male SqCLC patients, 93 had sarcopenia. Patients with sarcopenia were older and had a lower body mass index (BMI). Over an average follow-up of 20.8 months, 92 patients died. For all 130 patients, the mean OS was 13.3 months. Patients with sarcopenia had a significantly shorter OS and PFS than those without sarcopenia (OS, 12.4 ± 5.2 months vs. 15.5 ± 10.5 months, P = 0.028; PFS, 6.4 ± 2.9 months vs. 7.7 ± 4.2 months; P = 0.035). Multivariable analysis showed that sarcopenia was an independent prognostic factor for shorter OS and PFS. CT-determined sarcopenia is an independent prognostic factor for older patients with SqCLC receiving ICIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“skeletal muscle depletion, adipose infiltration, and altered body composition have been associated with survival, treatment tolerance, and adverse outcomes in patients with cancer, including lung cancer (11–14).”
In the citing paper
“Previous studies in patients with lung cancer have linked CT-derived measures of skeletal muscle, adiposity, and body composition with survival and other clinical outcomes (9–14).”
In the citing paper
“Sarcopenic patients were significantly older, had lower muscle mass and function, a lower BMI and a higher ECOG [9,27].”
From AI-Assistance Body Composition CT at T12 and T4 in Lung Cancer: Diagnosing Sarcopenia, and Its Correlation with Morphofunctional Assessment Techniques (2025) · cites this paper as [27]
In the citing paper
“Sarcopenic patients were significantly older, had lower muscle mass and function, a lower BMI and a higher ECOG [9,27].”
From AI-Assistance Body Composition CT at T12 and T4 in Lung Cancer: Diagnosing Sarcopenia, and Its Correlation with Morphofunctional Assessment Techniques (2025) · cites this paper as [27]
In the citing paper
“Sarcopenic patients were significantly older, had lower muscle mass and function, a lower BMI and a higher ECOG [9,27].”
From AI-Assistance Body Composition CT at T12 and T4 in Lung Cancer: Diagnosing Sarcopenia, and Its Correlation with Morphofunctional Assessment Techniques (2025) · cites this paper as [27]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472 · cited 1×
“Response evaluation was performed using a CT scan of the target lesions and classified according to the immune-related response evaluation criteria in solid tumors 23 .”
MethodMeasurement of skeletal muscle radiation attenuation and basis of its biological variation
Aubrey, J., Esfandiari, N., Baracos, V. E., Buteau, F. A., Frenette, J., Putman, C. T., & Mazurak, V. C. (2014) · Acta Physiologica · doi:10.1111/apha.12224 · Cited by 720 · cited 1×
“The CT HU thresholds were − 29 to + 150 for quantifying muscle 19 .”
BackgroundMyokines and Adipokines: Involvement in the Crosstalk between Skeletal Muscle and Adipose Tissue
Li, F., Li, Y., Duan, Y., Hu, C.-A. A., Tang, Y., & Yin, Y. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.10.003 · Cited by 288
The obesity paradox in cancer-moving beyond BMI
Strulov Shachar, S., & Williams, G. R. (2017) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0439 · Cited by 198 · cited 1×
“Therefore, BMI is not a perfect biomarker of body composition as it relies heavily on adiposity and cannot effectively represent body composition 32 .”
BackgroundCheng, K. Y., Chow, S. K., Hung, V. W., Wong, C. H., Wong, R. M., Tsang, C. S., Kwok, T., & Cheung, W. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12825 · Cited by 154 · cited 1×
“Dual-energy X-ray absorptiometry is the preferred go-to method for the measurement of skeletal muscle mass because of accuracy and repeatability 18 .”
Method
Research works printed but not linked: 28
- Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021). · DOI · Paper page
- Zhang, S. et al. Cancer incidence and mortality in China, 2015. J. Natl. Cancer Cent. 1(1), 2–11 (2021). · DOI · Paper page
- Cheng, T. Y. et al. The international epidemiology of lung cancer: Latest trends, disparities, and tumor characteristics. J. Thorac. Oncol. 11(10), 1653–1671 (2016). · DOI · Paper page
- Jemal, A. et al. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J. Natl. Cancer Inst. https://doi.org/10.1093/jnci/djx030 (2017). · DOI · Paper page
- Hirsch, F. R. et al. Lung cancer: Current therapies and new targeted treatments. Lancet 389(10066), 299–311 (2017). · DOI · Paper page
- Rami-Porta, R. et al. Lung cancer staging: A concise update. Eur. Respir. J. 51(5), 1800190 (2018). · DOI · Paper page
- Friedlaender, A. et al. Next generation sequencing and genetic alterations in squamous cell lung carcinoma: Where are we today?. Front. Oncol. 9, 166 (2019). · DOI
- Langer, C. J. et al. Incremental innovation and progress in advanced squamous cell lung cancer: Current status and future impact of treatment. J. Thorac. Oncol. 11(12), 2066–2081 (2016). · DOI
- Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379(21), 2040–2051 (2018). · DOI · Paper page
- Cruz-Jentoft, A. J. & Sayer, A. A. Sarcopenia. Lancet 393(10191), 2636–2646 (2019). · DOI · Paper page
- Bozzetti, F. Forcing the vicious circle: Sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Ann. Oncol. 28(9), 2107–2118 (2017). · DOI · Paper page
- Pring, E. T. et al. Cancer cachexia and myopenia-update on management strategies and the direction of future research for optimizing body composition in cancer—A narrative review. Cancer Treat. Rev. 70, 245–254 (2018). · DOI
- Yang, M. et al. Prognostic value of sarcopenia in lung cancer: A systematic review and meta-analysis. Chest 156(1), 101–111 (2019). · DOI · Paper page
- Shoji, F. et al. Relationship between preoperative sarcopenia status and immuno-nutritional parameters in patients with early-stage non-small cell lung cancer. Anticancer Res. 37(12), 6997–7003 (2017).
- Roch, B. et al. Cachexia-sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer 143, 19–26 (2020). · DOI
- Lyman, G. H., Lyman, C. H. & Agboola, O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10(6), 427–437 (2005). · DOI · Paper page
- DeSantis, C. E. et al. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J. Clin. 69(6), 452–467 (2019). · DOI · Paper page
- Prado, C. M. et al. Prevalence and clinical implications of sarcopenic obesityobesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol. 9(7), 629–635 (2008). · DOI · Paper page
- Charlson, M. E. et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 40(5), 373–383 (1987). · DOI · Paper page
- Zhao, L. et al. Association between Charlson comorbidity index score and outcome in patients with stage IIIB–IV non-small cell lung cancer. BMC Pulm. Med. 17(1), 112 (2017). · DOI
- Daly, L. E. et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br. J. Cancer 116(3), 310–317 (2017). · DOI · Paper page
- Shiroyama, T. et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. Sci. Rep. 9(1), 2447 (2019). · DOI · Paper page
- Bilen, M. A. et al. combined effect of sarcopenia and systemic inflammation on survival in patients with advanced stage cancer treated with immunotherapy. Oncologist 25(3), e528–e535 (2020). · DOI
- Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15(8), 486–499 (2015). · DOI · Paper page
- Tsang, N. M. et al. Overweight and obesity predict better overall survival rates in cancer patients with distant metastases. Cancer Med. 5(4), 665–675 (2016). · DOI
- Schlesinger, S. et al. Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: A prospective study and meta-analysis. Cancer Causes Control 25(10), 1407–1418 (2014). · DOI
- Berger, N. A. Obesity and cancer pathogenesis. Ann. NY. Acad. Sci. 1311, 57–76 (2014). · DOI · Paper page
- Fusco, D. et al. Comprehensive geriatric assessment in older adults with cancer: Recommendations by the Italian society of geriatrics and gerontology (SIGG). Eur. J. Clin. Invest. 51(1), e13347 (2021). · DOI
Cited by
Montero-Benitez, M. Z., Carmona-Llanos, A., Fernández-Jiménez, R., Román-Jobacho, A., Gómez-Millán, J., Modamio-Molina, J., Cabrera-Cesar, E., Vegas-Aguilar, I., Amaya-Campos, M. D. M., Tinahones, F. J., et al. (2025) · Cancers · doi:10.3390/cancers17193255 · Cited by 7
Sung, S., Choi, H. J., Jeong, S., Cho, W., Kim, Y. J., Cha, H., Min, C. H., & Kim, M. S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1946212
Metadata
- Authors
- Ying, L., Xu, L., Yang, J., & Zhang, Q.
- Venue
- Scientific Reports
- Published
- 2024-05-26
- Volume
- 14
- Issue
- 1
- ISSN
- 2045-2322
- Cited by
- 15
- References
- 5
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic significance of CT-determined sarcopenia in older patients with advanced squamous cell lung cancer treated with programmed death-1 inhibitors. https://app.cochat.ai/papers/10.1038/s41598-024-62825-2
- The paper
- Ying, L., Xu, L., Yang, J., & Zhang, Q. (2024). Prognostic significance of CT-determined sarcopenia in older patients with advanced squamous cell lung cancer treated with programmed death-1 inhibitors. Scientific Reports. https://doi.org/10.1038/s41598-024-62825-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.